The Blame Game

Given the positive impact DTC can have on patients – via helping the undiagnosed and driving persistence and compliance among those on treatment – how is it that this form of consumer promotion has earned such a negative reputation?

So who is it that feels DTC ads are wasteful, jacking up the cost of drugs – manipulating the public to request unnecessary drugs – and forcing the medical profession to treat with inappropriate medications?

No, it is not the physician. At least that’s what the results of a recent study, published in this publication in December 2009, indicated. These findings show that of 12,500 doctor-patient conversations in 2008, when DTC was brought up, 54 percent of the time it was first mentioned by the physician. And, four out of five times, the comments were favorable. Clearly, DTC is not a physician issue.

No, it is not the general public. Did you and I miss the hue and cry in the public marketplace to halt or extremely limit advertising of pharmaceuticals / devices? I think not. It’s not there. In fact, I’d wager that for the vast majority of consumers, DTC advertising is viewed as residing somewhere between an informative educational source (i.e., valuable), sometimes entertaining on a “hush-hush” topic (ED) to just another annoying advertisement that one has to tolerate. No doubt, ad placement is an issue for some (e.g., ED ads in front of young audiences) and for a few who think that advertising drives up the case of “everything.” Indeed, the argument is makeable that for some, the brief summary is proof that DTC ads answer to a higher authority of accuracy / truthfulness.

Yes, the pharma industry does have itself to blame in many cases for the low position in the public eye it finds itself. The fact that such prominent firms as Pfizer and Eli Lilly (and there have been others) who last year paid huge fines to settle charges that they had illegally marketed some specific drugs for unapproved use, certainly hampers the effort to raise the public perception of pharma. Moreover, there is a continued need for pharma to explain why some drugs for specialized, limited markets are hugely expensive. There is a need to tote the incredible successes of medicines and the good that they have provided.

In short, when you look to the medical profession itself, when you look at the patient/consumer community, they are not tarring and feathering DTC and driving it out of town. Rather, it is those who need the scapegoat of DTC to foster their own gaming needs who are distorting reality.

David Kweskin is a senior vice president at The Research Intelligence Group, a full-service qualitative and quantitative custom market research firm. For more information, visit www.trigsite.com. Kweskin can be reached by e-mail at dkweskin@trigsite.com, or by telephone at (203) 321-8528.